remydulery.bsky.social - Profile | ThreadSky | a Reddit-style client for Bluesky

AACR urges Congress to reaffirm its long history of steadfast and bipartisan support for medical research by ensuring that NIH has all of the resources needed to advance its lifesaving mission to prevent, diagnose, and treat cancer and other diseases: AACR.org/NIH

submitted 8 days ago • 0 comments

Excited to share this first-in-human evaluation of memory-like NK cells combined with an IL-15 super-agonist, with or without ipilimumab, in advanced head and neck cancer! Kudos to Roman Shapiro and Michal Sheffer for leading this work in the #RomeeLab. jhoonline.biomedcentral.com/articles/10....

submitted 12 days ago • 0 comments

This will kill science in the US. This is how China wins. Why is this not on the news? Why are people not more upset about this? grants.nih.gov/grants/guide...

submitted 19 days ago • 8 comments

Trump & Musk are making massive cuts to the National Institutes of Health. I know there is a lot going on right now, but this is one of worst things they have done so far, will affect cancer research and trials, the search for cures, innovation and competitiveness, our universities. Your lives.

submitted 18 days ago • 510 comments

Academic medicine colleagues, I worry we missed the boat on scientific communication. If we did a better job of explaining what we do and how we do it, half the country wouldn’t be so happy about defunding us right now.

submitted 17 days ago • 0 comments

Thank you Rémy for promoting this paper ! This confirmatory study reinforce the body of evidence to vaccine patients against COVID-19 BEFORE and AFTER anti-CD20 immunochemotherapy against Lymphoma

submitted 18 days ago • 1 comment

Important report in @nejm.org from @mskcancercenter.bsky.social CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 #CARTcells #mmsm www.nejm.org/doi/full/10....

submitted 20 days ago • 0 comments

Happy to share this study! We prospectively evaluated CD4, CD8 T-cell and serological responses to the #COVID19 mRNA vaccine in a B-cell lymphoma patients treated with anti-CD20 therapy. Kudos to Caroline Besson & @sylvainlamure.bsky.social for leading this work. www.frontiersin.org/journals/imm...

submitted 19 days ago • 1 comment

Here is another remarkable study by the LYSA, published in @Hemasphere-journal.bsky.social! It evaluates the efficacy of anti-PD1 therapy in extranodal NK/T cell lymphoma with matched cohort analysis. Kudos to Amira Marouf for leading this collaborative work. onlinelibrary.wiley.com/doi/full/10....

submitted 33 days ago • 1 comment

Happy to share our study on postoperative stage 0 Hodgkin lymphoma published in @hemasphere-journal.bsky.social Congrats to Audrey Couturier and Guillaume Manson for leading this work. Is surgery alone a curative option? Find some answers in our article! ⬇️ onlinelibrary.wiley.com/doi/10.1002/...

submitted 35 days ago • 0 comments

After CAR T therapy in France, only one patient developed a T cell malignancy, highlighting a low incidence risk. by Dulery R, Guiraud V (...) Houot R et 10 al. in Nat Med #MedSky 📖 read the article:

submitted 40 days ago • 0 comments

🎉Finally published🎉 Clearance of driver mutations after transplantation for myelofibrosis @nejm.org www.nejm.org/doi/full/10....

submitted 48 days ago • 0 comments

Happy to share our work published in Nature Medicine! We analyzed 3,066 patients from the French DESCAR-T registry who received #CARTcell therapy. Our findings indicate a very low risk of T-cell malignancy after CAR T-cell therapy: only 1 case (0.03%). www.nature.com/articles/s41...

submitted 49 days ago • 1 comment

Disappointing new study showing - once again - that women are leaving research careers at far higher levels than men If you're interested to read about strategies to reverse these types of curves, check out our recent #Cell perspective- link below ⤵️ #WomeninSTEM 👩‍🔬👩🏾‍🔬🧪 www.nature.com/articles/d41...

submitted 47 days ago • 12 comments

Analysis of 3,066 patients who received #CARTCell therapy in France, since 2018. Only one patient (0.03%) developed a T-cell malignancy after CAR T infusion, with insertion of the CAR into a tumor suppressor gene. Conclusion: there might be a very low risk of T-cell malignancy after CAR T therapy.

submitted 47 days ago • 1 comment

T cell malignancies after CAR T cell therapy in the DESCAR-T registry @naturemedicine.bsky.social @remydulery.bsky.social www.nature.com/articles/s41...

submitted 48 days ago • 0 comments

A French study of 3,066 patients who received CAR T-cell therapy found an extremely low incidence (0.03%) of T-cell malignancies post-treatment. Only one case was observed over six years, suggesting the treatment is largely safe in this regard. www.nature.com/articles/s41...

submitted 49 days ago • 1 comment

Amazing and very important work for the field. 👏🏽👏🏽👏🏽

submitted 49 days ago • 0 comments

Happy to share our work published in Nature Medicine! We analyzed 3,066 patients from the French DESCAR-T registry who received #CARTcell therapy. Our findings indicate a very low risk of T-cell malignancy after CAR T-cell therapy: only 1 case (0.03%). www.nature.com/articles/s41...

submitted 49 days ago • 1 comment

Here is a video where I discuss the management and treatment options for patients with DLBCL who are not eligible for CAR T-cell therapy. #VuMedi #CAR_T #lymsm #Medsky www.vumedi.com/video/treati...

submitted 51 days ago • 0 comments

From #ASH24 to inpatient leukemia service! Instead of posting articles I will be posting an abstract a day Day 1 - our IIT looking at InO plus TKI in newly diagnosed Ph+ ALL ashpublications.org/blood/articl...

submitted 77 days ago • 1 comment

Post-CAR MCL DESCAR-T registry: - 1-yr OS after brexu-cel failure 30% - post-CAR outcomes better with RT (ORR 50%) and BsAb (ORR 43%) - 1-yr OS 57% w/ BsAb - most deaths due to MCL, some infections 2nd #ASH24 dataset showing better outcomes w/ BsAb in MCL post-CAR setting. #lymsm

submitted 81 days ago • 0 comments

CAR-T outcomes based on nodal +/- extranodal @gloria_iacoboni #ASH24 - post-CAR OS worse if nodal+EN - ORR worse with increasing # of EN sites - sites w/ worse outcomes: bone, liver, GI, renal/adrenal, pancreas - network analysis reveals connected sites #lymsm #tcellrx

submitted 80 days ago • 0 comments

#ASH24 plenary: ketogenic diet & CAR-T efficacy - ketogenic diet➡️cytokine release & CAR expansion in mouse xenograft via beta-hydroxybutyrate - in pts, BHB correlates w/ CAR expansion and giving BHB to 3 pts enhanced T-cell oxphos Fascinating! BHB + CAR-T trial is open. #tcellrx

submitted 80 days ago • 0 comments

Brexu-cel ZUMA-2 in BTKi naive pts #ASH24 - 86 pts, mFU 16 mos - 1-yr PFS 75%, OS 90%; 1-yr DOR 80% for responders - 6% G3+ CRS, 21% G3+ ICANS! - COD: 7 deaths d/t AEs My preference is for liso-cel given better toxicity profile (or cytoreduce with BTKi). #lymsm #tcellrx

submitted 79 days ago • 0 comments

Excellent data with PEMBRO-GVD in relapsed #Hodgkin lymphoma in study by @mskcancercenter.bsky.social Alison Moskowitz - she will present additional data tomorrow #ash24 #lymsm

submitted 81 days ago • 0 comments

A highly anticipated new CAR-T cell therapy for B-cell ALL and a great news for the patients! Congratulations to Claire Roddie and the team behind the FELIX trial, leading to the FDA approval of Obecabtagene autoleucel. Read the full article here: www.nejm.org/doi/full/10....

submitted 86 days ago • 0 comments

If you're interested in Stem cell transplant and/or Cellular Therapy this is the list #bmtsm #CARTcells #leusm #mmsm #lymsm #MedSky #TcellRx go.bsky.app/7xxh8WW

submitted 96 days ago • 1 comment

🎉📢 Delighted to share our work from Princess Margaret Cancer Centre 🙌🏼 PTCy-based GvHD prophylaxis was associated with an improved GRFS, NRM, and OS 💪🏼 A big shout-out to @haemophage.bsky.social for his mentorship 🙌🏼 doi.org/10.1182/bloo... #MedSky #HemeSky

submitted 97 days ago • 4 comments